GeNeuro: upcoming investor meetings in San Francisco during the J.P. Morgan Healthcare Conference and in Paris at Biomed Event
Geneva, Switzerland, January 9, 2020 – 5:50pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases will participate to the LifeSci Advisors Corporate Access Event from January 13 to 16, 2020, in San Francisco, USA, concurrent with the J.P. […]
Le journal des biotechs
Carmat, Celyad, Hybrigenics, entretien avec Jesús Martin-Garcia, DG de Geneuro https://www.boursorama.com/videos/actualites/le-journal-des-biotechs-carmat-celyad-hybrigenics-entretien-avec-jesus-martin-garcia-dg-de-geneuro-3f8070f214454c6992f7208c995f342e
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
PNAS, July 23, 2019 https://www.pnas.org/content/116/30/15216
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019 https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf
ECTRIMS 2109 – Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks
Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study https://geneuro.ch/data/news/P1379-Ectrims-2019.pdf
Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
Frontiers in Genetics, July 11, 2019 https://www.frontiersin.org/articles/10.3389/fgene.2019.00655/full
Variation in proviral content among human genomes mediated by LTR recombination
Mobile DNA, December 18, 2018 https://geneuro.ch/data/news/2018-12-Mobile-DNA-Variation-in-proviral-content-among-human-genomes-mediated-by-LTR-recombination-Thomas-Perron-Feschotte.pdf
Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination
Glia, November 14, 2018 https://geneuro.ch/data/news/2018-11-Go-ttle-et-al.-GLIA.pdf
GNbAC1 shows efficacy on MRI measures of neurodegeneration in relapsing-remitting MS patients over 48 weeks
Robert Glanzman at the 26th Annual Meeting of the European Charcot Foundation (November 2018) in Baveno, Italy https://www.pnas.org/content/116/30/15216
HERV-W-Env involvement in human T1D pathogenesis
S. Levet, J. Joanou, N. Queruel, J.Pierquin & H. Perron https://geneuro.ch/data/news/18-05-22-Poster-ADA-2018-V2.pdf